NASDAQ: VNDA
Vanda Pharmaceuticals Inc Stock

$4.53+0.05 (+1.12%)
Updated Feb 5, 2025
VNDA Price
$4.53
Fair Value Price
$13.24
Market Cap
$264.14M
52 Week Low
$3.61
52 Week High
$6.75
P/E
-15.62x
P/B
0.49x
P/S
1.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$190.86M
Earnings
-$16.39M
Gross Margin
93.6%
Operating Margin
-9.48%
Profit Margin
-8.6%
Debt to Equity
0.19
Operating Cash Flow
-$18M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

VNDA Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VNDA's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
B
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VNDA
Ranked
#40 of 558

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VNDA news, forecast changes, insider trades & much more!

VNDA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VNDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VNDA ($4.53) is undervalued by 65.78% relative to our estimate of its Fair Value price of $13.24 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VNDA ($4.53) is significantly undervalued by 65.78% relative to our estimate of its Fair Value price of $13.24 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VNDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VNDA due diligence checks available for Premium users.

Valuation

VNDA fair value

Fair Value of VNDA stock based on Discounted Cash Flow (DCF)

Price
$4.53
Fair Value
$13.24
Undervalued by
65.78%
VNDA ($4.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VNDA ($4.53) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VNDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VNDA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-15.62x
Industry
-153.98x
Market
31.5x

VNDA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.49x
Industry
5.04x
VNDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VNDA's financial health

Profit margin

Revenue
$47.7M
Net Income
-$5.3M
Profit Margin
-11.2%
VNDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VNDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$645.1M
Liabilities
$103.9M
Debt to equity
0.19
VNDA's short-term assets ($432.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VNDA's short-term assets ($432.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VNDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VNDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.6M
Investing
$12.1M
Financing
$0.0
VNDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VNDA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
VNDAC$264.14M+1.12%-15.62x0.49x
AVIRC$263.52M+5.05%-1.51x0.57x
VSTMC$264.81M+1.36%-1.86x23.94x
SGMOB$262.90M+1.61%-1.70x6.72x
CADLC$260.78M+2.82%-4.64x-17.09x

Vanda Pharmaceuticals Stock FAQ

What is Vanda Pharmaceuticals's quote symbol?

(NASDAQ: VNDA) Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol VNDA. Vanda Pharmaceuticals stock quotes can also be displayed as NASDAQ: VNDA.

If you're new to stock investing, here's how to buy Vanda Pharmaceuticals stock.

What is the 52 week high and low for Vanda Pharmaceuticals (NASDAQ: VNDA)?

(NASDAQ: VNDA) Vanda Pharmaceuticals's 52-week high was $6.75, and its 52-week low was $3.61. It is currently -32.89% from its 52-week high and 25.48% from its 52-week low.

How much is Vanda Pharmaceuticals stock worth today?

(NASDAQ: VNDA) Vanda Pharmaceuticals currently has 58,308,144 outstanding shares. With Vanda Pharmaceuticals stock trading at $4.53 per share, the total value of Vanda Pharmaceuticals stock (market capitalization) is $264.14M.

Vanda Pharmaceuticals stock was originally listed at a price of $9.68 in Apr 12, 2006. If you had invested in Vanda Pharmaceuticals stock at $9.68, your return over the last 18 years would have been -53.2%, for an annualized return of -4.13% (not including any dividends or dividend reinvestments).

How much is Vanda Pharmaceuticals's stock price per share?

(NASDAQ: VNDA) Vanda Pharmaceuticals stock price per share is $4.53 today (as of Feb 5, 2025).

What is Vanda Pharmaceuticals's Market Cap?

(NASDAQ: VNDA) Vanda Pharmaceuticals's market cap is $264.14M, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vanda Pharmaceuticals's market cap is calculated by multiplying VNDA's current stock price of $4.53 by VNDA's total outstanding shares of 58,308,144.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.